The in vitro bacterial susceptibilities and pharmacokinetic properties of amikacin (BB-K8) were studied in newborn infants. Gram-negative bacteria and Staphylococcus aureus isolated from neonates were uniformly susceptible to 10 ,ug or less of amikacin per ml, and five Escherichia coli strains resistant to kanamycin were inhibited and killed by 5 ,ug or less of amikacin per ml. Mean peak serum concentrations of 17 to 20 ,ug/ml were observed 30 min after 7.5-mg/kg amikacin doses, and accumulation of drug in serum was not detected after repeated doses for 5 to 7 days. Intravenous infusion of amikacin over a 20-min period resulted in extremely low peak serum levels in four of eight infants studied. Serum half-life values were correlated inversely with postnatal age and renal clearances of amikacin. The volumes of drug distribution indicate that amikacin remains primarily in the extracellular fluid space of neonates. The lack of efficacy and safety data preclude the use of amikacin in neonates at this time.
Past experience has shown that microbial resistance to antibiotics emerges commonly in closed population areas such as nurseries and neonatal intensive care units where these drugs are used routinely. As a result, it is imperative to constantly monitor susceptibilities of commonly encountered pathogens in these high risk units and to evaluate new antimicrobial agents that offer promise for treatment of neonatal bacterial infections. Amikacin is a new aminoglycoside with broad antimicrobial activity similar to that of gentamicin (7) . The drug is not a suitable substrate for the common plasmid-associated enzymes responsible for microbial resistance to the other aminoglycosides. Studies in adults have demonstrated that the pharmacokinetic properties of amikacin are similar to those of kanamycin (3) .
Because of its potential usefulness in neonatal bacterial infections caused by organisms resistant to kanamycin and gentamicin, the antimicrobial activity against gram-negative bacteria isolated from neonates and the clinical pharmacology of amikacin in full-term and premature infants were studied.
MATERIALS AND METHODS
The susceptibility of 304 organisms cultivated from blood, cerebrospinal fluid, and urine of sick neonates and from stool cultures of healthy babies was determined by agar-plate dilution using a multiple inoculation apparatus (5 (Table 2) .
Clinical pharmacological studies. Serum concentration-time curves were determined in 32 infants given a single 7.5-mg/kg dose of amikacin (Fig. 1) . The curves for infants with birth weights under 2,000 g were similar to those for infants weighing 2,000 g or more at birth. Mean peak serum levels of 17 to 20 jAg/ml were detected 0.5 h after the dose in all infants regardless of birth weight. Individual peak values ranged from 10 to 26 ,g/ml. Mean values were inversely correlated with gestational and chronological ages (Fig. 3) and ranged from 7 to 8 h in low-birth-weight infants 1 to 3 days of age to 4 or 5 h in full-term infants 7 days of age or older. Volume of distribution and plasma clearance. The volumes of amikacin distribution during the first 3 days of life were largest in low-birth-weight infants (Table 3) . With increasing postnatal age the volumes diminished in the low-birth-weight infants and increased in the normal-birth-weight babies. The plasma clearance of amikacin did not change significantly during the neonatal period.
Intravenous versus intramuscular administration. Serum levels were measured after both an intramuscular and an intravenous amikacin dose (7.5 mg/kg) in eight infants. Serum concentration-time curves were comparable after the two routes of administration in four infants. In the other four infants the curves after the intravenous dose were flat, and peak serum concentrations of only 4 to 6 ,ug/ml were detected. By contrast, the peak serum values after intramuscular administration in these babies were 14 to 20 ,ug/ml. a Five or six infants were studied in each age group for the <2,000-and 5 2,000-g weight categories.
ug/ml, and accumulation of drug in serum after repeated administration was not observed. Peak serum values were independent of birth weight and chronological age, which is different from our previous studies with kanamycin where peak concentrations were correlated with birth weight and postnatal age (5a). Erratic amikacin levels after 20-min intravenous infusions were observed in four of eight infants studied. Because these four babies had the smallest birth weights it is possible that the volume of drug distribution in these infants after 4 days were comparable for the two drugs (5a). On the basis of these studies, amikacin may prove useful for therapy of neonatal infections caused by gram-negative bacteria resistant to kanamycin. A dosage schedule of an initial 10-mg/kg dose followed by 7.5-mg/kg doses administered intramuscularly every 12 h results in peak serum values that are within the therapeutic and safe range. Studies of safety and efficacy are currently underway in four nurseries in North, Central, and South America. Until these studies are completed, amikacin should only be used for specific clinical conditions where kanamycin and gentamicin are contraindicated and where the infant can be observed closely for evidence of drug toxicity.
